Opinion|Videos|September 27, 2024
Sequencing Options of Bispecifics in R/R MM
Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.
Melody Rasouli, MD, MBA, FACOG, discusses oncofertility gaps at NCI-designated cancer centers and ways to speed fertility referrals for patients.
Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.
In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.
Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.
![“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg?w=350&fit=crop&auto=format)
“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
2
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
3
How Is Subcutaneous Administration Changing Oncology Care Delivery?
4
FDA OKs Pirtobrutinib in Frontline CLL/SLL
5